** Shares of Adaptive Biotechnologies ADPT.O up 0.5% at $17.30 before the bell on Weds as co raises more capital than planned

** Seattle, Washington-based ADPT announces pricing private offering of $300 mln 0% convertible bonds due 2031

** Offering size increased from $250 mln; initial conversion price of $24.11 is 40% premium to stock's last sale of $17.22 on Tues

** Co intends to use net offering proceeds to repay OrbiMed purchase agreement, for general purposes and opportunistic initiatives in Minimal Residual Disease (MRD) business

** Late Mon, ADPT unveiled plans to separate its MRD and Immune Medicine businesses, with CEO and co-founder Chad Robins saying it's "the best way to unlock the full potential of both businesses, increasing their impact on patients and creating long-term value for shareholders"

** ADPT stock closed down 1.4% on Tues for about $2.8 bln market cap. Stock up 6% YTD and 67% over the past 12 months

** Avg rating of 8 analysts is "buy"; median PT $20.50, per LSEG